Serious adverse events · people with hepatorenal syndrome
Terlipressin showed no clear difference in serious adverse events compared with placebo or no intervention (low certainty).
1 finding from 1 review
Serious adverse events: cardiovascular events · people with hepatorenal syndrome
Terlipressin may leads to higher serious cardiovascular adverse events compared with placebo or no intervention (low certainty).
1 finding from 1 review
Abdominal pain · people with hepatorenal syndrome
Terlipressin showed no clear difference in abdominal pain compared with placebo or no intervention (low certainty).
1 finding from 1 review
Diarrhoea · people with hepatorenal syndrome
Terlipressin may leads to higher diarrhoea compared with placebo or no intervention (low certainty).
1 finding from 1 review
All‐cause mortality or other serous adverse events of the newborn
1 finding from 1 review
All‐cause mortality or other serous adverse events of the mothers
1 finding from 1 review
Newborn with HBsAg‐positive result
It is very uncertain whether hepatitis B immunoglobulin (HBIG) changes newborn with HBsAg‐positive result compared with no intervention (very low certainty).
1 finding from 1 review
Newborn with HBeAg‐positive result
It is very uncertain whether hepatitis B immunoglobulin (HBIG) changes newborn with HBeAg‐positive result compared with no intervention (very low certainty).
1 finding from 1 review
Newborn with HBV‐DNA‐positive result
Hepatitis B immunoglobulin (HBIG) may leads to lower newborn with HBV‐DNA‐positive result compared with no intervention (low certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality ( · people with hepatic encephalopathy
The intervention showed no clear difference in all‐cause mortality ( (low certainty).
1 finding from 1 review
Intervention not reported
Adverse events ‐ Change of/or withdrawal from treatment ( · people with hepatic encephalopathy
It is very uncertain whether the intervention changes adverse events ‐ Change of/or withdrawal from treatment ( (very low certainty).
1 finding from 1 review
Intervention not reported
Quality of life ( · people with hepatic encephalopathy
1 finding from 1 review
Intervention not reported
Plasma ammonia concentration (final and change scores) (μmol/L) ( · people with hepatic encephalopathy
1 finding from 1 review
Intervention not reported
No‐recovery (incomplete resolution of clinical symptoms) ( · people with hepatic encephalopathy
The intervention probably leads to lower no‐recovery (incomplete resolution of clinical symptoms) ( (moderate certainty).
1 finding from 1 review
Intervention not reported
Adverse events ‐ Overt hepatic encephalopathy ( · people with hepatic encephalopathy
The intervention may leads to lower adverse events ‐ Overt hepatic encephalopathy ( (low certainty).
1 finding from 1 review
Intervention not reported
Adverse events ‐ Change of/or withdrawal from treatment ( · people with hepatic encephalopathy
It is very uncertain whether the intervention changes adverse events ‐ Change of/or withdrawal from treatment ( (very low certainty).
1 finding from 1 review
Intervention not reported
Quality of life ( · people with hepatic encephalopathy
1 finding from 1 review
Intervention not reported
Plasma ammonia concentration (final and change scores) (μmol/L) ( · people with hepatic encephalopathy
1 finding from 1 review
Intervention not reported
All‐cause mortality ( · people with hepatic encephalopathy
It is very uncertain whether the intervention changes all‐cause mortality ( (very low certainty).
1 finding from 1 review
Intervention not reported
No‐recovery (incomplete resolution of clinical symptoms) ( · people with hepatic encephalopathy
It is very uncertain whether the intervention changes no‐recovery (incomplete resolution of clinical symptoms) ( (very low certainty).
1 finding from 1 review